CRSP Quote, Financials, Valuation and Earnings

Moderna has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -117.16%. CRISPR Therapeutics AG's return on equity of -18.65% beat Moderna's return on equity of -29.09%.

CRISPR Therapeutics AG has a consensus price target of $82.63, signalling upside risk potential of 118.7%. On the other hand Moderna has an analysts' consensus of $51.14 which suggests that it could grow by 103%. Given that CRISPR Therapeutics AG has higher upside potential than Moderna, analysts believe CRISPR Therapeutics AG is more attractive than Moderna.

CRISPR Therapeutics AG has a beta of 1.849, which suggesting that the stock is 84.861% more volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Moderna quarterly revenues of $956M. CRISPR Therapeutics AG's net income of -$37.3M is higher than Moderna's net income of -$1.1B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 3.06x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 20.79%. CRISPR Therapeutics AG's return on equity of -18.65% beat Novartis AG's return on equity of 27.64%.

CRISPR Therapeutics AG has a consensus price target of $82.63, signalling upside risk potential of 118.7%. On the other hand Novartis AG has an analysts' consensus of $112.26 which suggests that it could grow by 2.44%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

CRISPR Therapeutics AG has a beta of 1.849, which suggesting that the stock is 84.861% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.564, suggesting its less volatile than the S&P 500 by 43.554%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.53% to investors and pays a quarterly dividend of $3.87 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Novartis AG quarterly revenues of $13.6B. CRISPR Therapeutics AG's net income of -$37.3M is lower than Novartis AG's net income of $2.8B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 4.31x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -18.65% beat Roche Holding AG's return on equity of 23.8%.

CRISPR Therapeutics AG has a consensus price target of $82.63, signalling upside risk potential of 118.7%. On the other hand Roche Holding AG has an analysts' consensus of $46.62 which suggests that it could grow by 20.84%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.

CRISPR Therapeutics AG has a beta of 1.849, which suggesting that the stock is 84.861% more volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.111%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Roche Holding AG offers a yield of 3.53% to investors and pays a quarterly dividend of $1.36 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than Roche Holding AG quarterly revenues of --. CRISPR Therapeutics AG's net income of -$37.3M is higher than Roche Holding AG's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Roche Holding AG's PE ratio is 26.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 3.53x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 31.35%. CRISPR Therapeutics AG's return on equity of -18.65% beat Vertex Pharmaceuticals's return on equity of -3.23%.

CRISPR Therapeutics AG has a consensus price target of $82.63, signalling upside risk potential of 118.7%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.43 which suggests that it could grow by 2.5%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals.

CRISPR Therapeutics AG has a beta of 1.849, which suggesting that the stock is 84.861% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. CRISPR Therapeutics AG's net income of -$37.3M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 11.44x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.